JOINT FILING AGREEMENTJoint Filing Agreement • March 6th, 2024 • Corerx Inc • Pharmaceutical preparations
The undersigned hereby acknowledge and agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein, but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
January 19, 2024Corerx Inc • March 11th, 2024 • Pharmaceutical preparations • Delaware
MUTUAL NON-DISCLOSURE AND CONFIDENTIALITY AGREEMENTDisclosure and Confidentiality Agreement • March 11th, 2024 • Corerx Inc • Pharmaceutical preparations • North Carolina
This Mutual Non-Disclosure and Confidentiality Agreement (this “Confidentiality Agreement”) is made, effective as of October 27, 2023 (the “Effective Date”), by and between QHP Capital, L.P., a Delaware limited partnership, with a place of business at 4509 Creedmoor Road, Suite 403, Raleigh, North Carolina 27612 (“QHP”), and Societal CDMO, Inc., a Pennsylvania corporation, with a place of business at 1 E. Uwchlan Ave, Suite 112, Exton, Pennsylvania 19341 (“Company”), because QHP and Company desire to discuss and explore a possible negotiated business transaction between themselves or their Affiliates (as defined below) or to otherwise share Confidential Information (as defined below) between themselves or their Affiliates (the “Proposed Transaction”). In connection with the Proposed Transaction, QHP, in its discretion, may disclose to Company certain information that QHP considers nonpublic, confidential or proprietary in nature, and Company, in its discretion, may disclose to QHP cert
